Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00777348 | To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol | PHASE2 | COMPLETED | 62 | — | — | Nov 1, 2007 | Oct 1, 2008 | Feb 7, 2022 | 7 | Germany |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | DSCG + Reproterol |
| 2 | ACTIVE_COMPARATOR | DSCG |
| 3 | ACTIVE_COMPARATOR | Reproterol |
| 4 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Combination DSCG and Reproterol | DRUG | 1: |
Inclusion Criteria: * Female and male subjects aged 18 - 65 years * Exercise induced asthma with reversible airway obstruction: twice proven EIA defined as maximum decrease in FEV1 against the baseline value of at least 20% (first test results can be obtained during the last 12 months) * Baseline F...